

BIOMARIN PHARMACEUTICAL INC  
Form 4  
March 20, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BAFFI ROBERT**

(Last) (First) (Middle)

C/O BIOMARIN  
PHARMACEUTICAL INC., 105  
DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/18/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
SVP, Technical Operations

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D \$ 32.61	42,156	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	200	D \$ 32.62	41,956	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D \$ 32.63	41,856	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D \$ 32.65	41,756	D
	03/18/2008 <sup>(1)</sup>	03/18/2008	S	1,400	D \$ 32.66	40,356	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.67	40,256	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	200	D	\$ 32.69	40,056	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	364	D	\$ 32.7	39,692	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.71	39,592	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.72	39,492	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	700	D	\$ 32.73	38,792	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.74	38,692	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.748	38,592	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	1,500	D	\$ 32.75	37,092	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.756	36,992	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	112	D	\$ 32.76	36,880	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.77	36,780	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	200	D	\$ 32.78	36,580	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	200	D	\$ 32.82	36,380	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.84	36,280	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	300	D	\$ 32.85	35,980	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	1,100	D	\$ 32.86	34,880	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.89	34,780	D
Common Stock	03/18/2008 <sup>(1)</sup>	03/18/2008	S	100	D	\$ 32.92	34,680	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Table with 9 columns: 1. Title of Derivative Security (Instr. 3), 2. Conversion or Exercise Price of Derivative Security, 3. Transaction Date (Month/Day/Year), 3A. Deemed Execution Date, if any (Month/Day/Year), 4. Transaction Code (Instr. 8), 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5), 6. Date Exercisable and Expiration Date (Month/Day/Year), 7. Title and Amount of Underlying Securities (Instr. 3 and 4), 8. Price of Derivative Security (Instr. 5), 9. Number of Derivative Securities Beneficially Owned (Instr. 5). Includes sub-headers for Date Exercisable and Expiration Date, and Amount or Number of Shares.

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

BAFFI ROBERT
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949

SVP, Technical Operations

Signatures

/s/ G. Eric Davis, 03/20/2008
Attorney-in-Fact

\*\*Signature of Reporting Person Date

Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.